Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000653003 | SCV000774877 | uncertain significance | Norman-Roberts syndrome; Familial temporal lobe epilepsy 7 | 2020-11-06 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with RELN-related disease. This variant is present in population databases (rs143688278, ExAC 0.001%). This sequence change replaces aspartic acid with valine at codon 2352 of the RELN protein (p.Asp2352Val). The aspartic acid residue is moderately conserved and there is a large physicochemical difference between aspartic acid and valine. |
Prevention |
RCV004740388 | SCV005366415 | uncertain significance | RELN-related disorder | 2024-05-21 | no assertion criteria provided | clinical testing | The RELN c.7055A>T variant is predicted to result in the amino acid substitution p.Asp2352Val. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0023% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |